Blockbuster to be? Novartis snags a major win as FDA OKs one of its top 3 late-stage drugs Endpoints NewsAfter racking up a large batch of positive data demonstrating its ability to slow the rate of disease progression, Novartis $NVS today toasted an FDA approval of ...